Alignment Healthcare Inc (ALHC) Stock News

A securities fraud investigation into Alignment Healthcare continues following allegations that a former executive filed a whistleblower lawsuit claiming the company manipulated finances by misclassifying operating expenses as capital expenditures to artificially inflate adjusted EBITDA. The stock fell 16.7% on July 8, 2026, following the disclosure.

A whistleblower lawsuit alleges that Alignment Healthcare manipulated its finances by misclassifying $8-10 million in operating expenses as capital expenditures to artificially inflate adjusted EBITDA and report false positive earnings. The stock fell 16.7% on the news, injuring investors.

Alignment Healthcare's stock plummeted 59% between July and October 2026 after CMS downgraded its California HMO plan (H3815) from 4.0 to 3.5 Star Rating, making it ineligible for quality bonus payments. The company faces investor scrutiny over allegedly misleading statements about its confidence in maintaining bonus eligibility, with management refusing to discuss Star Rating positioning in September before the downgrade was publicly disclosed.

Law firm Kaplan Fox is investigating Alignment Healthcare (ALHC) for potential securities violations following a whistleblower complaint alleging accounting irregularities and misclassification of operating expenses as capital expenditures. The allegations artificially inflated the company's financial results and Adjusted EBITDA metrics. ALHC stock fell 16.7% on July 8, 2026, following the news.

Law firm Lowey Dannenberg is investigating Alignment Healthcare (ALHC) for potential federal securities violations following allegations by a former executive that the company manipulated finances by misclassifying $8-10 million in operating expenses as capital expenditures to artificially inflate adjusted EBITDA. The disclosure caused Alignment's stock to fall 16.7% on July 8, 2026.

Law firm Kaplan Fox is investigating Alignment Healthcare (ALHC) following a whistleblower complaint alleging accounting irregularities where millions in operating expenses were misclassified as capital expenditures, artificially inflating financial metrics including Adjusted EBITDA. The stock fell 16.7% on July 8, 2026, following the disclosure.

Hagens Berman is investigating Alignment Healthcare, Inc. (ALHC) following whistleblower allegations that the company engaged in accounting irregularities by misclassifying operating expenses as capital expenditures to artificially inflate EBITDA and financial metrics. The disclosure caused ALHC stock to plunge 16.7% in a single day, marking its worst performance since February 2024.

Law firm Kaplan Fox is investigating Alignment Healthcare for alleged accounting irregularities where millions in operating expenses were misclassified as capital expenditures, artificially inflating financial metrics including Adjusted EBITDA. The stock fell 16.7% on July 8, 2026, following the whistleblower complaint disclosure.

Hagens Berman is investigating Alignment Healthcare (ALHC) following whistleblower allegations that the company engaged in accounting irregularities by misclassifying operating expenses as capital expenditures to inflate EBITDA and financial results for 2024-2025. The disclosure caused ALHC stock to plunge 16.7% in a single day, marking its worst performance since February 2024.

Hagens Berman is investigating Alignment Healthcare (ALHC) following whistleblower allegations that the company engaged in accounting irregularities, misclassifying operating expenses as capital expenditures to inflate EBITDA and financial metrics. The disclosure caused ALHC stock to plunge 16.7% in a single day, marking its worst performance since February 2024.

Block & Leviton is investigating Alignment Healthcare, Inc. (ALHC) for potential securities law violations following allegations that a former executive filed a whistleblower lawsuit claiming the company manipulated finances to boost stock price and executive compensation. The stock fell approximately 16.72% following the report. The firm is also investigating Jefferies Financial Group and Unicycive Therapeutics for similar violations.

Law firm Johnson Fistel announced an investigation into Alignment Healthcare (NASDAQ: ALHC) following a whistleblower lawsuit filed by a former executive alleging the company manipulated its finances to boost stock price and executive compensation. The firm is investigating whether the company complied with federal securities laws and is seeking investors who suffered losses.

Joseph Konowiecki, vice chairman of Alignment Healthcare, sold 25,000 shares on June 26 for $575,000, reducing his direct holdings by 2.2%. While the sale aligns with his historical trading pattern and occurs under a pre-filed trading plan, the timing coincides with his recent step down from chairman and follows a pattern of executive selling over the past year. However, insider sales are predictive of stock declines less than half the time, and investors should weigh this against other company fundamentals.